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Recent changes in methods and techniques used in genetics-based
research have resulted in a call by researchers for large scale biobanks and
increased access to existing biobanks. These changes necessitate a reanaly-
sis of duties owed to human subjects of research. In the past, genetics re-
search usually involved examining the genes of people with a particular
disease and their families. It required tissue samples from people with a
disease and people likely to develop that disease. The participants tended to
be people affected by the disease, and they frequently developed relation-
ships with or felt connections to the principal investigator.
Now, improvements in sequencing technology make it possible to
compare the entire genomes of tens of thousands of people in order to lo-
cate genetic differences between people with specific illnesses and people
without those illnesses. Mutations that are associated with heart disease,
breast cancer, diabetes and other diseases with a multi-factorial basis have
been located using these genome-wide association studies. In addition to a
very large number of samples to ensure statistical accuracy, these studies
require gathering more than participants' genetic information and noting
whether they have one particular disease or not. Much more information
must be collected about each sample from the many thousands of partici-
pants because the more information that is gathered about participants'
samples, the more relationships between diseases can be examined and the
more types of research can be performed. Many entities, including univer-
sities, private companies, and governmental agencies such as the National
Institutes of Health, are initiating or expanding their support of large scale
genomics-based initiatives. Included in these efforts is a call for the in-
* J.D., Director of Research and Projects, Institute for Science, Law, and Technology, Chicago-
Kent College of Law. The author filed an amicus brief in Washington University v. Catalona, 490 F.3d
667 (8th Cir. 2007), on behalf of a patients' rights organization in support of defendant research partici-
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CHICA GO-KENT LAW REVIEW
creased collection of clinical and phenotypic information for each sample,
and an increased sharing of the samples.
However, when more information is known about the person who
provided a tissue sample, the potential for secondary uses of that sample
increases. It also increases the chances that research will be performed
beyond the scope of the participant's consent or that his or her confidential
health information will be divulged, especially as samples and information
are increasingly shared. When these breakdowns occur, participants may
lose trust in researchers and institutions. But participation in research de-
pends on trust; people will not participate in research if they do not trust the
researchers, institutions or companies conducting the research.
A longstanding ethical principle governing any research on human
beings has been that consent to participate in research must be voluntary.'
People have the right to not be researched upon without their consent. They
have the right to be told that they are participating in research, and to be
given any material information about the research that would affect their
initial willingness to participate and their willingness to continue their par-
ticipation in the research. They also have the right to withdraw from further
participation in research without penalty. 2 In the past, these principles were
based on the protection of bodily integrity and the right to be free from
unwanted touching. Applying these principles to non-genetics research
appears to be straightforward in certain circumstances. In the testing of
pharmaceuticals, for example, a potential research participant must be told
the nature of the study, that it is experimental, whether it is a placebo trial
and the implications of that type of research, that she can stop participating
in the trial at any time, and what the ramifications would be if she stopped
participating; if she discontinued her participation, the drug company could
no longer force her to ingest the drug. 3
But what do these principles mean when the research is performed on
blood or other tissue that has been removed from the body? Such samples
are most valuable if they are linked to identities and clinical information,
including whether a person has a certain disease, environmental exposures,
and other personal health information. The participants' tissue contains
their genes which can always be linked to a specific individual and the
information used to his or her detriment. Yet increasingly policymakers and
1. See, e.g., 45 C.F.R. § 46.116 (2007); 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG
MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW No. 10, at 181-82 (U.S. Gov't Printing Office,
1946-1949) [hereinafter NUREMBERG CODE].
2. E.g., 45 C.F.R. § 46.116(a)(8).
3. See 21 C.F.R. §§ 50.20-27 (2008).
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researchers argue that specific consent is not necessary in genetics re-
search 4 or that the use of tissue that does not have a person's name or other
information associated with it is exempt from the regulations governing
human research. 5 If this is the standard in ethical and research communi-
ties, it perhaps is not known to the people who provided the tissue.
The trend in medical research to use large collections of tissue sam-
ples and associated information raises questions: What are the duties and
responsibilities of investigators and institutions to the people who partici-
pate in biomedical research studies? How well do existing laws, regulations
and federal agencies protect research subjects when compared to long-
standing ethical principles guiding human subjects research? What is likely
to be the effect on research if the rights, interests and preferences of people
who participate in research are not protected?
I. ETHICAL AND LEGAL PRINCIPLES GOVERNING HUMAN SUBJECTS
RESEARCH
A. The Importance of Voluntary Participation in Research
The paramount ethical principle governing any research on human
beings is that participation in research must be voluntary. The ethical
guidelines governing human subjects research are set forth in the Nurem-
berg Code, 6 the Declaration of Helsinki, 7 and the Belmont Report. 8 The
first principle of the Nuremberg Code, an international standard for re-
search that was developed after Nazi physicians were convicted of research
abuses, is that the "voluntary consent of the human subject is absolutely
essential." 9 The World Medical Association provides the Declaration of
Helsinki to guide physicians and other researchers conducting medical
research. It similarly recognizes that human subjects of research must be
volunteers. 10 In 1979, a Presidential Commission issued the Belmont Re-
4. Bernice Elger and Arthur L. Caplan, Consent and Anonymization in Research Involving
Biobanks: Differing Terms and Norms Present Serious Barriers to an International Framework, 7
EMBO REPORTS 661, 664-65 (2006).
5. See infra Part II.C.
6. NUREMBERG CODE, supra note I, at 181-82.
7. WORLD MED. Ass'N, WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: ETHICAL
PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (2004), available at
http://www.wna.net/e/policy/pdf/l 7c.pdf [hereinafter DECLARATION OF HELSINKI].
8. THE NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF
HUMAN SUBJECTS OF RESEARCH (1979), available at http://www.hhs.gov/ohrp/humansubjects/
guidance/belmont.htm [hereinafter BELMONT REPORT].
9. NUREMBERG CODE, supra note 1, at 181.
10. DECLARATION OF HELSINKI, supra note 7, § 20. The Declaration of Helsinki states that medi-
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port, setting forth ethical principles that must underlie biomedical research-
ers' conduct, including respecting people as autonomous agents who
choose what shall or shall not happen to them. 11
The U.S. Congress has deemed it important to provide protections to
human research subjects. 12 Regulations governing the protection of partici-
pants in human research studies have been codified at 45 C.F.R. part 46
(known as the "Common Rule"). 13 The regulations provide "minimum"
standards of protection for research participants. 14 Though the regulations
apply only to federally funded research, many research institutions have
agreed to comply with the regulations in their non-federally funded re-
search. 15 Under the federal regulations, researchers and research institu-
tions must comply not only with the federal regulations, but also with state
laws that provide additional protections for research participants. 16
Federal research regulations codify the principle that participation in
research must be voluntary. 17 Participants have a right to be told their par-
ticipation is voluntary, that they do not have to participate, and that they
cal research involving human subjects "includes research on identifiable human material and data." Id.
11. BELMONT REPORT, supra note 8, §§ B.I, C.1. The National Commission set forth three
commonly repeated ethical principles of human subjects research: (1) Respect for Persons (which
became informed consent under the federal regulations); (2) Beneficience (that is, risk-benefit
assesment); and (3) Justice (addressing equitable selection of subjects). See id. § B. 1-3.
12. See Public Health Service Act, 42 U.S.C. § 289 (2006) (originally enacted as Health Research
Extension Act of 1985, Pub. L. No. 99-158, § 49 1(a), 99 Stat. 820, 873) The Act states that:
The Secretary [of Health and Human Services] shall by regulation require that each entity
which applies for a grant... for any project or program which involves the conduct of bio-
medical or behavioral research involving human subjects submit ... assurances satisfactory to
the Secretary that it has established (in accordance with regulations which the Secretary shall
prescribe) a board (to be known as an 'Institutional Review Board') to review biomedical and
behavioral research involving human subjects conducted at or supported by such entity in or-
der to protect the rights of the human subjects of such research.
42 U.S.C. § 289(a).
13. 45 C.F.R. pt. 46 (2007).
14. 45 C.F.R. § 46.103(b).
15. All institutions that seek to participate in HHS-supported human subjects research must com-
plete a Federalwide Assurance (FWA) application stating that they will conduct the research in com-
pliance with HHS guidelines and policies. Office for Human Research Prots., U.S. Dep't of Health and
Human Servs., Assurances (Oct. 25, 2006), http://www.hhs.gov/ohrp/assurances/assurances_ in-
dex.html; see also 45 C.F.R. § 46.103(a). The OHRP maintains a publicly searchable database for
approved FWAs and registered institutions. Office for Human Research Prots., U.S. Dep't of Health
and Human Servs., Search the Office for Human Research Protections Database (Current Data),
http://ohrp.cit.nih.gov/search/asearch.asp (last visited Jan. 23, 2009). This database is comprehensive
and allows users to search for specific domestic and international institutions, id., but the way the search
engine is designed makes it impractical to compile a detailed list of institutions that have an approved
FWA.
16. 45 C.F.R. § 46.101(0 (providing that the existence of the federal regulations "does not affect
any state or local laws or regulations which may otherwise be applicable and which provide additional
protections for human subjects").
17. 45 C.F.R. § 46.116.
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can withdraw from the study at any time. 18 Participation should not be
coerced; the potential subjects must also be told that declining to participate
will entail no loss of benefits to which they are otherwise entitled. 19
Not all people who participate in research are protected by federal or
state regulation. There are many private biotechnology firms that conduct
non-federally supported genetics and other research that are not required to
follow the federal regulations. 20 Moreover, some private foundations also
support a substantial amount of biomedical research. 21 Only a very small
minority of individual states have laws governing human subjects research.
This may leave many research participants without federal protection.
Biomedical research nears the $100 billion mark in the United
States. 22 Driving its growth, however, is not just know-how and stick-to-
itivness. Research depends on people and their tissue. These people provide
pieces of themselves, literally. Their tissue may lead to the next big medi-
cal breakthrough and may be worth millions or even billions of dollars.
Given such compelling factors, the most important protection to the partic-
ipants is the ethical mandate and the legal assurance that they cannot be
forced to participate in research. Individuals-and their tissue-should not
be used for research unless they consent.
When this standard is violated, controversy is likely to follow. Dis-
putes over tissue, the secondary use of tissue provided for another purpose,
and sharing samples between researchers are decades old. In the late
1960's, geneticist James Neel and a group of researchers ventured into the
Amazon to collect blood from members of the Yanomami Tribe, a secluded
group of indigenous peoples living at the border of Brazil and Venezuela. 23
Like many isolated groups, the Yanomami Tribe is an attractive target for
researchers seeking to track genetic markers for certain diseases or study
genetic mutation rates. 24 In Neel's study, researchers told the Yanomami
that they would use these samples for a brief medical study on genetic
markers of diseases, as well as to study the diseases present in the Ama-
18. Id. §46.116(a)(8).
19. Id.
20. See Editorial, Board Games: The Way Research on Human Subjects is Overseen in the United
States Requires Reform, 448 NATURE 511, 512 (2007). Scholars and leading journals decry this lack of
oversight in the United States. See, e.g., id.
21. Hamilton Moses III et al., Financial Anatomy of Biomedical Research, 294 JAMA 1333, 1335
(2005).
22. Between 1994 and 2003, funding for biomedical research nearly doubled (when adjusted for
inflation) to reach $94.3 billion. Moses et al., supra note 21, at 1336.
23. Charles C. Mann, Anthropological Warfare, 291 SCIENCE 416, 419 (2001).
24. See David Glenn, Blood Feud, 52 CHRON. HIGHER EDUC., Mar. 3, 2006, at A- 14, A- 16; Mann,
supra note 23, at 419.
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zon. 25 According to the Yanomami, researchers said that after the study
was complete, the samples would be destroyed or returned. 26 However,
over forty years later, the samples collected by Neel's research group are
now circulating among several laboratories, even though the original expe-
riments have been completed. 27 Yet the Yanomami tribe never consented
to have their blood given to other researchers for other projects. 28 They
seek the return of the samples for destruction in accord with their cultural
and spiritual beliefs. 29 Similar disputes between researchers and other indi-
genous people, such as the Karitiana and the Surui peoples of Brazil, have
resulted in opposition to the research and created a distrust of researchers. 30
B. The Importance of Informed Consent to Participate in Research
For consent to be truly voluntary, people must be given sufficient
information to make a reasoned decision about whether or not to participate
in the study. Consent must be "informed" and the decision must be auto-
nomous. Most genetics studies are not designed to benefit the participant
directly, and participating in studies is not necessary for a patient's care.
Many researchers even expressly inform participants that they will not
provide the participant with clinically significant information they might
discover as a result of the research. 31 It is possible, or even likely, that a
participant will receive no benefit for participating in the study, and, in fact,
may not be able to afford diagnostics or therapeutics (drugs or devices)
developed as a result of clinical trials.
25. See Glenn, supra note 24, at A-16.
26. See id. at A-14. In exchange for their participation in the study, tribes such as the Karitiana
and the Yanomami were promised medical benefits, including the measles vaccination. Larry Rohter, In
the Amazon, Giving Blood but Getting Nothing, N.Y TIMES, June 20, 2007, at Al. However, the vacci-
nations only exacerbated the measles epidemic in the area because the Yanomami were given a cheap,
outdated vaccine. Mann, supra note 23, at 419.
27. Glenn, supra note 24, at A-14.
28. See id.
29. Researchers not only discarded the original plan without obtaining the consent of the Yano-
mami, but they also disregarded the religious and cultural values of the tribe. For example, the Yano-
mami believe that all parts of a person, including blood, must be destroyed once that person passes
away. Id. The Yanomami are now horrified to think that parts of their deceased ancestors are frozen in
laboratories across the world. Id. For further discussion of this controversy and ethics in the field of
anthropology, see ROBERT BOROFSKY, YANOMAMI: THE FIERCE CONTROVERSY AND WHAT WE CAN
LEARN FROM IT (2005).
30. See Rohter, supra note 26, at A-I, A-4.
31. Henry T. Greely, The Uneasy Ethical and Legal Underpinnings of Large-Scale Genomic
Biobanks, 8 ANN. REV. GENOMICS & HUM. GENETICS 343, 359 (2007). For further discussion of ethical
issues pertaining to direct and incidental findings made in the course of clinical research see generally
Susan M. Wolf et. al, Managing Incidental Findings in Human Subjects Research: Analysis and Rec-
ommendations, 36 J.L. MED. & ETHICS 219 (2008); Symposium, Incidental Findings in Human Sub-
jects Research: From Imaging to Genomics, 36 J.L. MED. & ETHICS 216 (2008).
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Informed consent is required even if there is no physical risk to a par-
ticipant, and even if there is no physical touching. There are risks inherent
in participating in genetics research, including psychological harm (for
example, if a person finds out she or a family member has a propensity to
develop a certain disease). Participants might discover new information
about family relationships, such as a different paternity or sibling relation-
ship that is contrary to what they had previously believed. There is the risk
that research participants might be discriminated against by employers,
educational institutions, and insurers. 32 People have lost their insurance
merely by participating in research protocols investigating a particular ge-
netic disease, even if they do not have the genes that cause the disease, let
alone the disease itself.33 Once tissue is removed from a person, the risk
exists that research beyond the scope of their consent will be carried out.
The risk also exists that a medical professional has an incentive to perform
unnecessary procedures to obtain additional tissue for research. 34
A committee of the National Academy of Sciences on genetics re-
search noted that, because research on tissue presents risks, "It is not ethi-
cally or legally acceptable to ask research participants to 'consent' to future
but yet-unknown uses of their identifiable DNA samples. ' 35 Currently, we
32. The Genetic Information Nondiscrimination Act of 2008 (GINA), passed on May 21, 2008,
provides some protection in the employment and insurance realms against discrimination based on
genetic information (where "genetic information" includes participation in a genetics research study).
See generally Pub. L. No. 110-233, 122 Stat. 881 (2008). For the Act's definition of "genetic informa-
tion," see id. § 101(d), 122 Stat. at 885 (amending Employee Retirement Income Security Act of 1974
(ERISA), 29 U.S.C. § 1 191b(d) (2006)). GINA prohibits employers from using genetic information to
make employment decisions; however, it does not prevent employers from gathering genetic informa-
tion about individuals in some instances. Id. § 202, 122 Stat. at 907-08. A plaintiff may have difficulty
proving that an adverse employment decision was based on the genetic information, and even if an
employee does prove discrimination, courts still may not award damages if the employer can show that
it would have taken the same actions regardless of a discriminatory motive. Civil Rights Act of 1991,
42 U.S.C. § 2000e-5(g)(2)(B) (2006) (amending Civil Rights Act of 1964, 42 U.S.C. § 2000e-5(g)
(2006)). Similarly, while insurers can gather genetic information in certain circumstances, they are not
allowed to use that information to adjust premiums or change coverage eligibility requirements. Genetic
Information Nondiscrimination Act of 2008 § 101(a)(2), 122 Stat. at 883 (amending Employee Retire-
ment Income Security Act of 1974 (ERISA), 29 U.S.C. § 1182(b) (2006)); § 102(a)(1), 122 Stat. at 888
(amending Public Health Service Act, 42 U.S.C. § 300gg-l(b) (2000)); § 103(a), 122 Stat. 896 (amend-
ing Internal Revenue Code of 1986, 26 U.S.C. § 9802(b) (2006)); § 104(a), 122 Stat. 899 (amending
Social Security Act, 42 U.S.C. § 1395ss(s)(2) (2000)). However, if an insurer can cite another reason
for raising premiums or denying coverage, it would be difficult to prove that an insurer discriminated on
the basis of genetic information. Moreover, GINA does not apply to long-term-care insurance, disability
insurance, or life insurance.
33. Lo~i B. ANDREWS, FUTURE PERFECT: CONFRONTING DECISIONS ABOUT GENETICS 133
(2001).
34. For example, a physician in California convinced a patient he needed to undergo medical
procedures to harvest bone marrow, blood and other tissue from the patient even though his cancer had
been cured. Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 481 (Cal. 1990).
35. COMM. ON HUMAN GENOME DIVERSITY, NAT'L RESEARCH COUNCIL, EVALUATING HUMAN
GENETIC DIVERSITY 65 (1997).
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cannot fully predict research that may one day be possible. Years ago we
lacked the technology to undertake many types of genetics research that are
common today. For these reasons, a research participant should be pro-
vided with even more information about the research than a person con-
senting to a routine medical procedure or intervention necessary for his or
her care. 36 But how the increased call for large numbers of samples can be
balanced with participants' right to voluntary and informed consent has yet
to be fully determined. Asking for blanket consent to all future uses of the
tissue when we do not know what the research will entail and what the
risks and benefits are initially seems inadequate.
The federal research regulations preclude research on an individual
and on an individual's tissue without that individual's informed consent. 37
To protect participants in federally funded research, "[a] human subject is
entitled to all material information. '38 Material information is that which is
required for a participant to make a reasoned and informed decision wheth-
er to incur certain risks by participating in the research. Information that
would affect a potential participant's willingness to participate is de facto
"material," as it affects the decision-making process. Information that must
be provided to the potential participant includes: the type of research that
will be performed; a description of risks and benefits to the participant or to
others; alternative procedures or treatments; the extent to which confiden-
tiality will be maintained; and information about who to contact should the
participant have questions or wish to withdraw from research.39 Depending
on the type of research, material information might also include a statement
explaining: that the research entails unforeseeable risks; what the conse-
quences are if a participant decides to withdraw; that significant findings
impacting the participant's decision to continue participation will be pro-
vided; and the number of subjects involved in the study.40
The federal regulations distinguish between two types of tissue: that
which is a byproduct of a medical procedure, such as pathological or diag-
nostic specimens, and that which is collected specifically for research pur-
poses.41 As the federal regulations are currently written, research
conducted on the former category is considered exempt from the informed
consent protections otherwise accorded human subjects in federal research
if the specimens are: (1) already existing when the research was underta-
36. See, e.g., BELMONT REPORT, supra note 8, § C.1.
37. 45 C.F.R. §§ 46.101(b)(4), 46.116 (2007).
38. Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 844 (Md. 2001).
39. 45 C.F.R. § 46.116(a).
40. Id. § 46.116(b).
41. See id. § 46.101(b)(4).
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ken; (2) were not collected for research purposes; and (3) are publicly
available or are not affiliated with a patient's identifying information.42
Tissue from the latter category is not exempt.
The case of Washington University v. Catalona illustrates the difficult
issues raised in this new era of biotechnology research. 43 The defendant in
the case, Dr. William Catalona, is an internationally renowned prostate
cancer surgeon and researcher. 44 Two decades ago, he started asking his
patients if they were willing to let him use their tissue removed during their
cancer biopsies and surgeries, their blood, and other bodily materials for his
research.45 Thousands of men and their families provided tissue to be used
in Dr. Catalona's research over the years. 46
Eventually, Dr. Catalona's then employer, Washington University,
began to realize the financial value of the tissue he had collected, ultimately
pegging the figure at over one million dollars. 47 A dispute arose as to
whether Dr. Catalona could send samples to a biotechnology company for
research purposes without the University receiving financial compensation
in return. 48 As the relationship with Washington University deteriorated,
Dr. Catalona decided to move his research and practice to another universi-
ty. 49 Six thousand patients sent forms to Washington University, directing
it to send their samples to Dr. Catalona at his new institution.50
In response, Washington University filed a lawsuit against Dr. Catalo-
na, seeking a declaratory judgment that it was the owner of the research
participants' samples. 51 In February 2005, the federal district court sua
42. Id. Because a patient's genetic information is the ultimate identifier, this exemption does not
make sense when applied to tissue samples.
43. See generally Wash. Univ. v. Catalona, 437 F. Supp. 2d 985 (E.D. Mo. 2006), aff'd, 490 F.3d
667 (8th Cir. 2007), cert. denied, 128 S.Ct. 1122 (2008), and cert. denied sub nom. Ward v. Wash.
Univ., 128 S.Ct. 1122 (2008).
44. Id. at 988. For a thoughtful discussion of the Washington University v. Catalona case, see Lori
Andrews, Who Owns Your Body? A Patient's Perspective on Washington University v. Catalona, 34
J.L. MED. & ETHICS 398 (2006). Any portions of the discussion used are used with author's permission.
45. See Opening Brief for Defendant-Appellant, William J. Catalona, M.D. at 7, Wash. Univ. v.
Catalona, 490 F.3d 667 (8th Cir. 2007) (Nos. 06-2286 & 06-2301).
46. Catalona, 437 F. Supp. 2d at 988-89.
47. Complaint for Declaratory Judgment at 14, Wash. Univ. v. Catalona, 437 F. Supp. 2d 985
(E.D. Mo. 2006) (No. 4:03CV01065SNL).
48. See Transcript of Hearing Vol. 3 at 32-33, Wash. Univ. v. Catalona, 437 F. Supp. 3d 985
(E.D. Mo. 2006) (No. 4:03CV01065SNL). Internal communication revealed that Washington Universi-
ty was unwilling to share the samples for free; it believed the samples Dr. Catalona wanted to share
were worth nearly $100,000. Id. at 30-33 (discussing an e-mail from Jon Kratochvil, Business Devel-
opment Director, Washington University, to Theodore Cicero, Vice-Chancellor for Research, Washing-
ton University).
49. See Opening Brief for Defendant-Appellant, William J. Catalona, M.D., supra note 45, at 11.
50. Id. at 12. The forms had been sent to the patients by Dr. Catalona.
51. Complaint for Declaratory Judgment, supra note 47, at 1.
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sponte ordered a hearing to be held to determine the sole issue of "[w]ho
owns the... [b]iorepository materials at issue in this case?" 52 Shortly be-
fore the hearing, the judge joined eight research participants as necessary
parties over Washington University's objections. 53 At the hearing, the re-
search participants testified that when they agreed to participate in research,
they intended to allow Dr. Catalona to use their tissue for his prostate can-
cer research. 54 They also pointed to the informed consent documents given
to them by the University which referred to "the use of your tissue for re-
search" and reiterated the patient's rights to his tissue: the forms used
phrases such as "your tissue" and "your blood sample and pathologic spe-
cimen," repeatedly acknowledging the men's retention of rights in their
own tissue. 55 The informed consent documents promised the men that if
they changed their mind about participating in research, they could with-
draw from the research and even direct Washington University to destroy
their sample. 56
Washington University countered that the men had given it a gift of
their tissue and it, therefore, had acquired ownership of the tissue.57 Yet not
one of the consent forms stated that the research participant was making a
gift to the University or that the University would become the owner of the
tissue. The University argued that it had the "sole discretion" to use the
participants' samples as it wished, in spite of provisions in the contracts to
the contrary. 58 However, if Washington University intended to claim it
owned the tissue and could use it in any manner, this was material informa-
52. Wash. Univ. v. Catalona, No. 4:03CV01065SNL (E.D. Mo. Feb. 11, 2005) (order setting
permanent injunction hearing to commence on April 11, 2005).
53. See Wash. Univ. v. Catalona, No. 4:03CV01065SNL (E.D. Mo. Mar. 14, 2005) (order joining
patients as necessary parties). No party seemed to know that the hearing that was to be held less than
one month before the research participants were added to the case would be case dispositive. Plaintiff's
Memorandum in Opposition to Interveners' Expedited Application for Leave to Intervene at 8, Wash.
Univ. v. Catalona, 437 F. Supp. 985 (E.D. Mo. 2006) (No. 4:03CV01065). In fact, when Washington
University objected to the research participants' motion to intervene, it suggested that they should be
added after the hearing, if at all, to prevent any delay to the hearing. Id. This unusual procedural posture
effectively deprived the research participants of their right to conduct discovery-Washington Universi-
ty would not have had to answer any discovery they propounded until after the hearing. Additionally,
the research participants were given little time to prepare for the hearing-preparation which would
entail reviewing the record and documents already produced by each side during the nineteen months
that the case had been pending. Their attorneys also had to schedule and prepare witnesses for the
hearing, and prepare cross examination, opening and closing statements, and exhibits.
54. Transcript of Hearing, supra note 48, at vol. 2, 71-72 (testimony of Richard Ward); id. at vol.
1, 158-59 (testimony of James Ellis); id. at vol. 1, 211 (testimony of Thomas McGurk).
55. Appendix of Appellee Volume 4 Trial Exhibits at 812-37, 907, 937, Wash. Univ. v. Catalona,
490 F.3d 667 (8th Cir. 2007) (Nos. 06-2286 & 06-2301); Joint Exhibit Appendix of Appellants at 1,
Wash. Univ. v. Catalona, 490 F.3d 667 (8th Cir. 2007) (Nos. 06-2286 & 06-2301).
56. Wash. Univ. v. Catalona, 437 F. Supp. 2d 985, 990 (E.D. Mo. 2006).
57. Id. at 994.
58. Complaint for Declaratory Judgment, supra note 47, at 53.
[Vol 84:1
WHAT IS OWED PARTICIPANTS IN BIOTECHNOLOGY RESEARCH?
tion that it was required to tell potential participants. It is information that
would have affected the participants' willingness to participate, and the
lack of this information hindered their ability to make an informed decision
about whether to participate.
After the hearing, the trial judge ruled that the informed consent doc-
uments were "inconsequential" and declared that Washington University is
the owner of the tissue. 59 The United States Court of Appeals for the
Eighth Circuit upheld the trial court's decision without considering the
applicable federal regulations. 60 It did hold, however, that the research
participants retained the right to direct the University to destroy or stop
using their tissue.61
What are the implications of the Catalona case for biomedical re-
search and the standards of voluntary and informed consent in research
studies? The decision that Washington University is the owner of the tissue
provided by the men allows the University to perform stigmatizing or ethi-
cally objectionable research on the participants' tissue, or sell it to a biotech
company for profit. This is not what the research participants intended. The
patients agreed to participate in Dr. Catalona's research studies because
they wanted to contribute to research that could help their families and
future generations avoid the same disease that afflicted them. 62
This is exactly the type of altruistic actions that medical research has
depended on in the past-people providing tissue to be used for a specific
purpose to which they agreed and for which they were promised it would
be used. If people learn that they have no right to support the research of
their choice, that promises made to them about the research are "inconse-
quential," that their tissue can be sold to the highest bidder, and that they
cannot stop research on themselves at their discretion, they will not partici-
pate in research studies. The negative effects on the institution are obvious:
litigation, distrust of researchers, an inability to recruit research partici-
pants, bad publicity, and a loss of funding. Clearly this is a lose-lose situa-
tion for both individuals and researchers.
59. Catalona, 437 F. Supp. 2d at 998, 1002.
60. Wash. Univ. v. Catalona, 490 F.3d 667, 677 (8th Cir. 2007).
61. Id. at 675 ("The [research participants'] subsequent rights to their biological materials were
expressly limited to the option to discontinue participation in the study to avoid answering additional
questions, donating more biological materials, or allowing their biological materials to be used for
further research.").
62. All testifying research participants stated that they did not intend to give their tissues to Wash-
ington University as a gift; rather, they merely intended to allow Dr. Catalona to use their tissues as part
of his research on prostate cancer. Transcript of Hearing, supra note 48, at vol. 2, 71-73 (testimony of
Richard Ward); id. at vol. 1, 157-58 (testimony of James Ellis); id. at vol. 1, 211 (testimony of Thomas
McGurk).
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C. Participants Must Be Allowed to Withdraw from Research
Hand-in-hand with the axiom that participation in research must be
voluntary is the principle that research participants must be able to stop
their participation in research on their tissue at their discretion. If research
is continued after consent is withdrawn, participation is no longer volunta-
ry. The Nuremberg Code mandates that the human subject must be allowed
to bring the experiment to an end. 63 The federal regulations require that the
participant must be told that he or she may discontinue participation at any
time without penalty, 64 and must be told the consequences of discontinuing
the research. 65 In genetics research, continuing research upon participants'
samples without their consent is not only inconsistent with the principle of
informed consent, but it also could be harmful to the participants' interests
or contrary to their religious or other beliefs. The right to withdraw should
continue even if the samples or information have been shared with re-
searchers at other institutions or with biotechnology companies. But if the
right to withdraw does not mean this, it is material information that must be
told to potential participants.
Some organizations have argued that when a research participant ex-
ercises his or her right to withdraw from biomedical research, the research-
ers can take the person's name off the tissue sample and continue to use
it.66 In Catalona, for example, the participants were promised that they
could withdraw their consent at any time. 67 The trial court held that this
meant if a participant changed his mind about participating in research,
Washington University retained the right to strip his name off his sample
and continue to use it.68 But the participants argued this is contrary to the
letter and the spirit of voluntary and informed consent. On appeal, the court
of appeals recognized the research participants' option of disallowing their
biological materials to be used for future research.69
63. THm NUREMBERG CODE para. 9, reprinted in THE NAZI DOCTORS AND THE NUREMBERG
CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 2 (George J. Annas & Michael A. Grodin eds.,
1992).
64. 45 C.F.R. § 46.116(a)(8) (2007).
65. Id. § 46.116(b)(4).
66. See, e.g., Brief for Amici Curiae Cornell University et al. as Supporting Plaintiff-Appellee at
6, 25, Wash. Univ. v. Catalona, 490 F.3d 667 (8th Cir. 2007) (Nos. 06-2286 & 06-2301).
67. Wash. Univ. v. Catalona, 437 F. Supp. 2d 985, 990 (E.D. Mo. 2006).
68. Id. at 999. The Office for Human Research Protections (OHRP), a part of the U.S. Department
of Health and Human Services (HHS), issued a draft guidance in late 2008, entitled GUIDANCE ON
IMPORTANT CONSIDERATIONS FOR WHEN PARTICIPATION OF HUMAN SUBJECTS IN RESEARCH IS
DISCONTINUED, (DRAFT GUIDANCE) (2008). The OHRP will finalize the guidance after it reviews
written comments on the proposed Guidance. 73 Fed. Reg. 231, 72,804-72,805 (proposed Dec. 1,
2008).
69. Wash. Univ. v. Catalona, 490 F.3d 667, 675 (8th Cir. 2007).
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People's attitudes regarding the storage of their tissue and the possibil-
ity of future research being undertaken on their samples reflects the impor-
tance of informing potential participants what will be done with their tissue
should they choose to withdraw from the study. Potential research partici-
pants are concerned about what is done with their tissue after the research
they consented to is completed. A survey conducted of 100 healthy adults
found that 42% said they would want to be informed if their tissues were
going to be stored after donation. 70 Thirty-five percent of respondents ex-
pressed a desire to be consulted if future research was to be undertaken on
stored their tissue samples.71
Another study queried participants in a long-term research project
tracking mental disease in the general population regarding their willing-
ness to participate in an additional phase of the research by contributing a
blood or buccal (cheek swab) sample. 72 Since these individuals were will-
ing to participate in such a long-term project regarding a sensitive medical
diagnosis (mental illness), one might expect that this group would be more
willing to provide samples for research. Yet, over one-quarter of the total
participants either refused to provide a sample or would not consent to
unlimited use of their genetic specimens. 73
Consent forms given to research participants frequently offer different
options for the uses of their tissue-for example, whether the institution
can share the tissue with other institutions, whether it can use the tissue in
future research without additional consent, or whether the person would
like to be recontacted for permission. In a study analyzing the responses on
different variations of National Institutes of Health consent forms between
2000 and 2002, almost one-fifth of participants given the option between
being recontacted before their tissue was used in the future or authorizing
all future research chose to be recontacted. 74 When participants were given
the option between refusing all future research, authorizing all future re-
search, or being recontacted before future use, 26% chose to be recon-
tacted. 75 These figures are even higher for people who had not already
70. M.L. Goodson & B.G. Vernon, A Study of Public Opinion on the Use of Tissue Samples from
Living Subjects for Clinical Research, 57 J. CLINICAL PATHOLOGY 135, 136 (2004).
71. Id.
72. Briana Mezuk et al., Participant Characteristics That Influence Consent for Genetic Research
in a Population-Based Survey: The Baltimore Epidemiologic Catchment Area Follow-up, 11
COMMUNITY GENETICS 171, 171-72 (2008). In that study, 83% of participants consented to provide
either a blood or buccal (cheek swab) sample. Id. at 172-74.
73. Id. at 173-74. The genetic tests specified in the consent forms were associated with dementia,
diabetes, depression, and cardiovascular disease. Id. at 173.
74. Donna T. Chen et al., Research With Stored Biological Samples: What Do Research
Participants Want?, 165 ARCHIVES OF INTERNAL MED. 652, 652, 654 (2005).
75. Id. at 654.
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agreed to participate in research on tissue but were being asked about their
potential participation.76 This indicates that even a sizable number of
people who are willing to participate in future research still want to retain
both control over their tissue and the ability to make a contemporaneous
choice.
D. Participants Cannot Be Made to Waive Certain Rights
Waivers of liability are common in consent forms for medical proce-
dures. But for certain economic, ethical, moral, financial, and other public
policy reasons, people cannot be forced to-and indeed are not allowed
to-give up certain rights. 77 Research participants similarly cannot be re-
quired-or even asked-to give up certain rights. The federal regulations
recognize this by prohibiting research subjects from waiving either their
legal rights to redress for negligence or their legal rights to their tissue. 45
C.F.R. § 46.116 provides:
No informed consent, whether oral or written, may include any exculpa-
tory language through which the subject or the representative is made to
waive or appear to waive any of the subject's legal rights, or releases or
appears to release the investigator, the sponsor, the institution or its
agents from liability for negligence. 78
As interpreted by government agencies, "legal rights" include the
participants' rights in their tissue, such as property rights or the right to
stop others from using it.79 A plain reading of this section, giving due im-
port to the comma after "legal rights" which separates that phrase from
"negligence," supports a conclusion that it was meant to prohibit more than
just waivers of negligence.
The Office for Human Research Protection (OHRP), the agency
charged with enforcing the federal regulations and protecting participants
in federally supported research, 80 has provided research institutions with
examples of forbidden exculpatory language, including: "By consent to
participate in this research, I give up any property rights I may have in
bodily fluids or tissue samples obtained in the course of the research. ' 81 In
contrast, acceptable language under 45 C.F.R. § 46.116 includes: "By con-
76. Id.
77. See generally DAN B. DOBBS, THE LAW OF TORTS 542 (2000).
78. 45 C.F.R. § 46.116 (2007).
79. "[T]he right to exclude others [is] 'one of the most essential sticks in the bundle of rights that
are commonly characterized as property."' Dolan v. City of Tigard, 512 U.S. 374, 384 (1994) (quoting
Kaiser Aetna v. United States., 444 U.S. 164, 176 (1979)).
80. See 42 U.S.C. § 289(b) (2006).
81. OFFICE FOR PROTECTION FROM RESEARCH RISKS, 'EXCULPATORY LANGUAGE' IN INFORMED
CONSENT (1996), http:l/www.hhs.gov/ohrp/humansubjects/guidance/exculp.htm.
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senting to participate, you authorize the use of your bodily fluids and tissue
samples for the research described above."' 82 The interpretation of the ex-
culpatory language prohibition by the OHRP comports with the U.S. Food
and Drug Administration's (FDA) interpretation of the exact same lan-
guage. The FDA has stated that the term "donation" is prohibited in in-
formed consent form language (and even in accompanying informational
brochures) because it impermissibly suggests that the research participant is
waiving a legal property right in the tissue. 83 Many institutions have agreed
to abide by the OHRP and the FDA's interpretation of this prohibition on
exculpatory language. 84
Subsequent to the Catalona decision, the University asked the OHRP
to review the trial and appellate courts' opinions and the language used in
the University's informed consent documents. The OHRP confirmed that
language in informed consent documents requesting individuals waive
legal rights they have in their tissue is exculpatory. 85
Although institutions have no need to own participants' tissue, one
reason they might prefer to do so is because it gives them more latitude
with the samples. If this is forbidden by the federal regulations and by ethi-
cal standards, institutions and researchers owe participants a duty to not
assert ownership claims or to ask participants for more than the use of their
82. Id. (emphasis added). The OHRP has enforced this regulation against universities who use
forbidden language, such as language requiring participants to "give up your property fights that you
may have in your bodily fluids, substances, or tissues." Letter from Carol J. Weil, Compliance Over-
sight Coordinator, Div. of Human Subject Prots., Office of Human Research Prots., to John C. McDo-
nald, Chancellor/Dean, La. State Univ. Health Sci. Ctr. Shreveport (Jan. 25, 2006),
http://www.hhs.gov/ohrp/detrm-letrs/YR06/jan06a.pdf. In deciding the Catalona appeal, the Eighth
Circuit ignored this rule and declined to review the University's use of improper language in its in-
formed consent documents. See Wash. Univ. v. Catalona, 490 F.3d 667, 675-76 n.7 (8th Cir. 2007).
83. See U.S. Food and Drug Administration, Guidance for Institutional Review Boards and Clini-
cal Investigators: 1998 Update, Question 52 (citing 21 C.F.R. § 50.20 (2008) (providing an effectively
identical prohibition on exculpatory language as 45 C.F.R. § 46.116 (2007))),
http://www.fda.gov/oc/ohrt/irbs/faqs.html (last visited Jan. 23, 2009).
84. See, e.g., Illinois State University, Exculpatory Language: Informed Consent,
http://www.rsp.ilstu.edu/research/exculpatory.shtml (last visited Jan. 29, 2009); Stanford University:
Research Compliance Office, Basic Research Consent Requirements 6,
http://humansubjectsstanford.edu/research/documents/ConsentGuidance.doc (last visited Jan. 29, 2009;
University of Nevada, Las Vegas, Exculpatory Language in Informed Consent Documents,
http://research.unlv.edu/OPRS/consent-exculpatory-language.htm (last visited Jan. 29, 2009).
85. Letter from Ivor A. Pritchard, Acting Dir., Office for Human Research Prots., to Samuel L.
Stanley, Jr., Vice Chancellor for Research, Wash. Univ. Sch. of Med. 2a, 5a (Nov. 29, 2007) (on file
with the author). The University tried to use the letter as a concession on the OHRP's part that examples
it has given as exculpatory language are just examples and not actually binding. See Brief for the Res-
pondent in Opposition at 23-24 n.5, Catalona v. Wash. Univ., 128 S.Ct. 1122 (2008) (Nos. 07-521 &
07-525). In doing so, the University glossed over the fact that the OHRP had unequivocally stated that
the language was forbidden, that it would enforce the prohibition against such language in the future,
and that it had ordered the University to remove such language from any forms it might currently be
using. See Letter from Ivor A. Pritchard to Samuel L. Stanley, Jr., supra, at 5a.
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tissue. If it is not forbidden, then a consensus should be reached and poten-
tial participants must be given this material information before agreeing to
participate.
E. Participants Must Be Given the Right to Choose the Studies in Which
They Will Participate
As part of informed consent, people must be told that they are partici-
pating in a research study and about the nature of the research that will be
undertaken. 86 People have strong attitudes towards the research they will
participate in and what can be done with their body parts and tissue. For
example, some people oppose embryonic stem cell research and would not
provide their tissue to be used in such research. Other people oppose the
patenting of human genes for religious, moral or other reasons, and would
not participate in research that would lead to this result. In a survey of 100
healthy adults in the United Kingdom, 82% of respondents indicated they
would be willing to donate tissues samples for cancer research; 65% would
be willing to donate tissues for research on genetic disorders; 59% would
consent to research on general knowledge of tissues or for testing different
medicines; and only 26% would be willing to donate tissues for research on
genetic cloning. 87 A survey of Jewish persons found that the participants
were the most likely to be willing to have their stored DNA samples used
in research into preventable medical illnesses (87%), mental illnesses
(87%), and alcoholism (85%), and the least likely to agree to studies about
frugality (60%) and homosexuality (72%).88 If people cannot choose what
research studies are performed on them and on their body parts, and if they
cannot stop research, they will simply stop joining research studies.
Pure common sense, as well as ethical and legal standards, tells us that
just because a person consents to one type of research or research by a par-
ticular researcher, the person would not necessarily consent to a different
type of research, or to research undertaken by a different researcher, at a
different institution, or at a company. In a study examining the genetic
causes of heart disease, 29% of African American participants indicated
that they did not want their tissue shared beyond the confines of the specif-
ic research protocol to which they consented.89 One obvious solution might
86. 45 C.F.R. § 46.116(a)(1) (2007).
87. Goodson & Vernon, supra note 70, at 136.
88. Marc D. Schwartz et al., Consent to the Use of Stored DNA for Genetics Research: A Survey
of Attitudes in the Jewish Population, 98 AM. J. MED. GENET. 336, 336 (2001). The authors noted that
the sample size was small and cautioned against making broad generalizations based on the results of
the survey which had been conducted years earlier.
89. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NATIONAL INSTITUTES OF HEALTH,
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seem to be to simply exclude people who do not agree to the unfettered
sharing of their tissue. However, excluding these individuals could lead to
skewed or biased results. Additionally, it could be coercive to decline to
enroll people who want to participate in studies but will not consent to the
sharing of their tissue in outside research. Consent must be sought under
circumstances that "minimize the possibility of coercion or undue influ-
ence." 90 Telling people they can only participate if they agree to tissue and
data sharing may place an undue and improper influence on their autonom-
ous decision making.
It is likely that people participate in studies of diseases that are impor-
tant to them; for example, the family of a person who has diabetes may
agree to participate in diabetes studies, just as they may choose to donate
money to the American Diabetes Association, instead of to some other
cause. People may choose to participate in studies they believe will help
them, their families, or others afflicted with the same disease.9 1 A study
undertaken to examine breast cancer patients' views and interest in receiv-
ing information about research studies found that, while "a few" partici-
pants expressed hope that the research undertaken on their tissue samples
would benefit them, "more" participants responded that they donated their
tissue in order to help others-either women in general or their family
members-suffering from breast cancer.92 Biotechnology research depends
on the altruistic intent of people who provide their time and their tissue to
be used in research. Taking away their right to choose their causes could
reduce participation in studies.
Another reason a participant may want to consent only to certain stu-
dies is that certain types of research may be stigmatizing to a person or to
REQUEST FOR INFORMATION MODIFICATIONS TO THE NHLBI POLICY FOR DISTRIBUTION OF DATA
FROM CLINICAL TRIALS AND EPIDEMIOLOGY STUDIES: EXECUTIVE SUMMARY (2006), available at
http://www.nhlbi.nih.gov/funding/policies/rfi-genome.htm (discussing the Jackson Heart Study's
recommendations to modify NHLBI's policy for distribution of data).
90. 45 C.F.R. § 46.116.
91. A group of African Americans surveyed identified three main reasons for participating in a
medical research study: (1) to help themselves or a loved one; (2) altruism; and (3) financial compensa-
tion. Vicki S. Freimuth et al., African Americans' Views on Research and the Tuskegee Syphilis Study,
52 SOC. SCI. & MED. 797, 797, 803-04 (2001). A group of parents considering enrolling their children
in a genetics research study identified three main reasons for allowing their children to participate in the
genetic study: (1) to help their own child; (2) to help others; and (3) to contribute to scientific know-
ledge. Lynn Gillam et al., Enhancing the Ethical Conduct of Genetic Research: Investigating Views of
Parents on Including Their Healthy Children in a Study on Mild Hearing Loss, 32 J. MED. ETHICS 537,
537, 539 (2006).
92. Kimberly A. Kaphingst et al., Views of Female Breast Cancer Patients Who Donated Biologic
Samples Regarding Storage and Use of Samples for Genetic Research, 69 CLINICAL GENETICS 393,
394-95 (2006). The study does not quantify the data "a few" and "more." The twenty-six participants in
the study were female breast cancer patients who had previously consented to donate blood or tissue
samples for breast cancer research at the Dana-Farber Cancer Institute in Boston. Id. at 394.
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the particular group to which the person belongs. Recent studies have tried
to link genetics to race or ethnic groups, thus creating the possibility that
some groups will become known as a greater insurance risk, less healthy,
or more expensive to treat. Research studying the genetic causes of mental
illness, alcoholism, or criminal propensities are other examples of such
studies. In 2006, a researcher made the controversial claim that he had dis-
covered a "warrior" gene in the Maori Tribe, which allegedly makes them
more aggressive, more violent, and more likely to be criminals.93 The Mao-
ri and others protested this claim as stigmatizing and scientifically ques-
tionable. 94
Particular groups of patients are already mistrustful of established
medical institutions.95 Certain minority groups, as well as women, whose
rights have been abused or ignored for years, 96 or who have not been given
the opportunity to benefit from research,97 have been shown to be less like-
ly to participate in human research in general, and genetics research in
particular.98 Taking this one step further, it is even possible that people will
not seek medical care if they cannot trust that their tissue will not be taken
and used in medical research against their will. This is especially a concern
for individuals in minority groups, who have already been shown to be less
likely to seek medical care for existing conditions due to apprehension
about what an institution will do with their tissue. 99
In a survey of over 1000 Vanderbilt patients, only 76% of African
American respondents (as compared to 93% of Caucasian respondents) felt
that leftover blood and tissues taken during routine medical procedures
should be used in anonymous medical research. 100 African American par-
93. Janine Bennetts & Tamara McLean, Warrior Gene Slammed by Maori, MAORI PARTY.ORG,
Aug. 9, 2006, http://www.maoriparty.com/index.php?option=comcontent&task=view&id-444&
Itemid=92; Maori 'Warrior' Gene Linked to Aggression, NEW ZEALAND HERALD, Aug. 9, 2006,
http://www.nzherald.co.nz/health/news/article.cftn?c-id=204&objectid=10395334&pnum=0.
94. Bennetts & McLean, supra note 93; Maori 'Warrior' Gene Linked to Aggression, supra note
93.
95. E.g., Giselle Corbie-Smith et al., Attitudes and Beliefs of African Americans Toward Partici-
pation in Medical Research, 14 J. GEN. INTERNAL MED. 537, 541 (1999).
96. ANDREWS, supra note 33, at 77-79, 90-92.
97. Corbie-Smith et al, supra note 95, at 540; Freimuth et al., supra note 91, at 803.
98. Geraldine M. McQuillan et al., Consent for Genetic Research in a General Population: The
NHANES Experience, 5 GENETICS MED. 35, 39 (2003).
99. Rayna Rapp, Refusing Prenatal Diagnosis: The Meanings of Bioscience in a Multicultural
World, 23 Sci. TECH. & HUM. VALUES (SPECIAL ISSUE) 45, 49, 51 (1998).
100. Jill M. Pulley et al., Attitudes and Perceptions of Patients Towards Methods of Establishing a
DNA Biobank, 9 CELL TISSUE BANKING 55, 55, 59 (2008). In spite of the fact that over a quarter of the
African American survey participants did not agree that blood samples drawn during routine clinical
care should be retained and used for research that is linked to medical records that have had certain
identifiers removed, Vanderbilt has implemented a plan to amass 300,000 blood samples in five years
for genetic research. Id. at 55. Vanderbilt will not seek individual patient consent for the collection;
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ticipants in the long-term mental health study were 50% less likely to con-
sent to storage of their sample in a biobank for use in unspecified future
genetic research. 10 1 A study that surveyed cancer patients in Indiana pro-
duced similar results, with members of minority groups less likely to allow
tissue samples to be used in unspecified future research, especially if that
research investigated other diseases or other types of cancer than their
own. 102
There are also groups that will not consent to certain types of re-
search. 103 In one case, a researcher collected blood samples from members
of the Havasupai Tribe, a Native American group that lives an isolated
existence in the Grand Canyon. 104 According to members of the tribe, the
researcher told the tribal elders she was undertaking diabetes research on
the samples, a disease that affects the tribe in a much higher percentage
than in the general population. 105 But the researcher had already filed grant
applications for schizophrenia research when she allegedly made this repre-
sentation. 106 The samples were shared with researchers at other universities
and were used not only for schizophrenia research, but also for origins and
migration studies, which conflicted with the tribe's religious beliefs. 107 The
tribe and its members filed a lawsuit against the researcher and her univer-
sity. 108 Other Native American groups have indicated their support for the
rather, it will "widely publicize" the project and patients must affirmatively opt-out. Id. Overall, almost
5% of those surveyed were decisively opposed to the research, and 16% were skeptical. Id. at 61. A
survey conducted by Vanderbilt researchers prior to implementation of the DNA Databanking project
found that only 32% of patients recalled seeing informational posters that were placed in phlebotomy
areas to provide information about the program and how to opt out. Jill M. Pulley et al., Evaluation of
the Effectiveness of Posters to Provide Information to Patients About a DNA Database and Their
Opportunity to Opt Out, 8 CELL TISSUE BANKING 233, 235-36 (2007).
101. Mezuk, supra note 72, at 173.
102. Paul R. Helfi et al., Cancer Patients' Attitudes Toward Future Research Uses of Stored Hu-
man Biological Materials, 2 J. EMPIRICAL RES. ON HUM. RES. ETHICS, Sept. 2007, at 15, 16-18.
103. For a discussion of the need for group consent see Debra Harry, Indigenous Peoples and Gene
Disputes, 84 CHI-KENT L. REv. 147 (2009).
104. See Rex Dalton, When Two Tribes Go to War, 430 NATURE 500, 500 (2004).
105. Id. at 500-01.
106. Id. at 501.
107. Lori Andrews, Havasupai Tribe Sues Genetic Researchers, 4 L. & BIOETHICS REP. 10, 10
(2004).
108. See Havasupai Tribe v. Ariz. State Univ. Bd. of Regents, No. S-0300-CV-20040146 (Coconi-
no County Super. Ct. filed Mar. 12, 2004); Tilousi v. Ariz. State Univ. Bd. of Regents, No. S-0300-CV-
2004-0115 (Coconino County Super. Ct. filed Feb. 26, 2004). After being removed to federal court and
then remanded back to state court, a state trial court judge dismissed on procedural grounds both the
Havasupai Tribe's claims and the claims of the individual members of the tribe. See Havasupai v. Ariz.
State Univ. Bd. of Regents, No. CV2005-013190 (Maricopa County Super. Ct. Aug. 28, 2007) (order
dismissing claims); Havasupai, No. CV2005-013190 (Apr. 30, 2007) (order dismissing claims). The
dismissal was reversed on appeal and the case was appealed to the Arizona Supreme Court. See Hava-
supai v. Ariz. State Univ. Bd. of Regents, No. CA-CV 07-0454 (Ariz. Ct. App. Nov. 28, 2008); Tilousi
v. Ariz. State Univ. Bd. of Regents, No. CA-CV 07-0801 (Ariz. Ct. App. Nov. 28, 2008); The Arizona
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Havasupai people, 109 and one tribe has declined to participate in a study for
which federal funds had already been approved because of the Havasupai
situation. It could take decades to rebuild trust and reestablish relationships
with groups such as this, if at all possible. Thirty years after the Tuskegee
Syphilis Study, some African Americans link a distrust of researchers to
the infamous study, saying research participants should expect dishonesty
and nondisclosure from investigators. 110
Federal agencies, in an attempt to address these complex issues, have
created plans that might not completely take people's opinions about their
tissue and the use of it in research into consideration.
II. SHARING OF INFORMATION, DATA AND SAMPLES: Two FEDERAL
PLANS
The National Institutes of Health (NIH) and the National Cancer Insti-
tute (NCI) have each created plans for data, information, or sample sharing
in research they support. Analyzing how these policies evolved, the public
response to the proposed policies, and the duties potentially owed to re-
search participants in the context of these federal policies illustrates the
extent to which the rights of participants are protected; where shortcomings
might exist; and where protections might go beyond those which are re-
quired, serving as an example for other research projects.
A. NIH G WAS Data Sharing
In the spring of 2006, the NIH released its proposed policy for data
sharing in genome-wide association studies (GWAS).III GWAS involve
searching for genetic variation across the entire human genome and at-
tempting to link genetic traits with observable traits (such as weight) or a
disease. 112 It varies from non-GWAS research, which typically looks at a
Supreme Court granted review with respect to the appeals of two defendants, allowing claims against
Theresa Markow and Arizona State University to go forward.
109. Letter from Beverly Becenti-Pigman, Chairman, Health and Human Res. Review Bd., The
Navajo Tribe, to Milton D. Glick, Executive Vice President & Provost, Ariz. State Univ. (Mar. 21,
2006) (on file with author); NAT'L CONG. OF AM. INDIANS, RESOLUTION #SAC-06-019: SUPPORTING
THE HAVASUPAI INDIAN TRIBE IN THEIR CLAIM AGAINST THE ARIZONA BOARD OF REGENTS
REGARDING THE UNAUTHORIZED USE OF BLOOD SAMPLES AND RESEARCH (2006), available at
http://www.ncai.org/ncai/resolutions/doc/SAC-06-019.pdf.
110. Giselle Corbie-Smith et al., Attitudes and Beliefs of African Americans Toward Participation
in Medical Research, 14 J. GEN. INTERN. MED. 537 (1999).
111. Request for Information (RFI): Proposed Policy for Sharing of Data Obtained in NIH Sup-
ported or Conducted Genome-Wide Association Studies (GWAS), 71 Fed. Reg. 51,629 (proposed Aug.
30, 2006).
112. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
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small portion of the genome. Tissue samples are not all that is needed for
GWAS studies; researchers also need clinical and phenotypic data about
the person who provided the sample to find associations between genetic
variation and a physical characteristic or disease manifestation. 113 The NIH
solicited comments from the public, policy organizations, and investigators,
and held a public town hall meeting in November 2006.114 The final po-
licy1 15 was issued on August 28, 2007, and became effective on January
25, 2008.116
The NIH has stated that one of the main goals of its GWAS data shar-
ing policy is to facilitate broad and consistent access to data through the
creation of a centralized data repository.11 7 The agency views increased
access to data used in gene studies as a means to identify common genetic
factors that influence health and disease, to improve predictability of dis-
ease, and, ultimately, to advance personalized medicine. 118 Under the final
policy, all investigators who are funded by the NIH to conduct analyses of
genetic variation are expected to submit descriptive information about their
studies to a centralized repository at the NIH. 119 Although the data reposi-
tory will not include actual physical specimens (those will be maintained
by the original researchers), it will include the resulting analyses of thou-
sands of single nucleotide polymorphisms and related data. 120
General information about the studies, including the protocol, ques-
tionnaires, study manuals, variables measured, and any other supporting
documentation, will be available to the public and other researchers
through the GWAS data repository.121 Genotypic and phenotypic data
tion Studies (GWAS), 72 Fed. Reg. 49,290,49,290 (proposed Aug. 28, 2007). For a perspective on why
GWAS might be a research method of limited utility in the long term, see Nicholas Wade, A Dissenting
Voice as the Genome is Sifted to Fight Disease, N.Y. TIMES, Sept. 16, 2008, at F3.
113. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,290-91.
114. Request for Information (RFI): Proposed Policy for Sharing of Data Obtained in NIH Sup-
ported or Conducted Genome-Wide Association Studies (GWAS), 71 Fed. Reg. at 51,629, 51,631.
Overall, the NIH received 196 written comments from various professional societies, patient advocacy
groups, privacy groups, individual scientists, and private citizens. Policy for Sharing of Data Obtained
in NIH Supported or Conducted Genome-Wide Association Studies (GWAS), 72 Fed. Reg. at 49,291.
115. The final Policy for Genome-Wide Association Studies (GWAS) is set forth at 72 Fed. Reg.
49,294. The background of the policy, the summary of the public comments, and other policy discus-
sions are set forth at 72 Fed. Reg. 49,290-94. When the final policy was issued in August 2007, the
NI stated that it was still in the process of developing informational materials relating to informed
consent for data submitted to the repository. Id. at 49,292-93.
116. Id. at49,294.
117. Id. at49,291.
118. Id. at 49,290-91.
119. Id. at49,295.
120. See id. at 49,291,49,295.
121. Id. at42,295.
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(such as blood pressure, weight, and psychiatric information); exposure
information (such as drug use and environmental factors); pedigree infor-
mation (including information about familial relationships); and analyses of
such data, including genetic associations with observable traits, will be
made available to researchers and investigators at both domestic and for-
eign academic and commercial institutions through a controlled access
process. 122 Some of the information in the database will be available on-
line. 123
The NIH acknowledged that during the public comment period, many
respondents expressed concern over the highly sensitive nature of the in-
formation that the data repository will contain and the potential for this data
to be used to identify people or to create social stigmatization or discrimi-
nation. 124 Respondents noted that it is becoming increasingly possible to
connect genetic information with individual observable traits (such as
height and weight), with the risk of developing certain diseases, or even
with certain behaviors.125 In its final policy, the NIH attempted to address
these concerns by providing detailed information about how submitted data
is to be anonymized. 126 Under the initial proposed policy, the submitting
institution was required to remove the names and other "identifying infor-
mation" from the data, replacing it with a random, unique code that was to
be held by the submitting institution. 127 Under the final policy, this re-
quirement is described as "de-identiflying]" all data submissions. 128 "De-
identified" means: (1) the identities of research participants cannot be easi-
ly ascertained or associated with the data by the repository staff or by sec-
ondary users; (2) the eighteen identifiers stated in the Health Insurance
Portability and Accountability Act (HIPAA) Privacy Rule 129 are removed;
122. See id. NIH Data Access Committees (DAC's), consisting of federal staff, will determine
whether a researcher's application (as approved by his or her home institution) to access the data (in-
cluding individual level information) will be approved; "[o]utside experts may be consulted as neces-
sary." NAT'L INSTS. OF HEALTH, NIH POINTS TO CONSIDER FOR IRBs AND INSTITUTIONS IN THEIR
REVIEW OF DATA SUBMISSION PLANS FOR INSTITUTIONAL CERTIFICATIONS UNDER NIH'S POLICY FOR
SHARING OF DATA OBTAINED IN NIH SUPPORTED OR CONDUCTED GENOME-WIDE ASSOCIATION
STUDIES (GWAS) 7 (2007), http://grants.nih.gov/grants/gwas/gwasptc.pdf.
123. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-




127. Request for Information (RFI): Proposed Policy for Sharing of Data Obtained in NIH Sup-
ported or Conducted Genome-Wide Association Studies (GWAS), 71 Fed. Reg. 51,629, 51,630 (pro-
posed Aug. 30, 2006).
128. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,295.
129. 45 C.F.R. § 164.514(b)(2) (2007). The identifiers include names; addresses; dates relating to
the individual (such as birth date and date of admission to the hospital), except for the year; telephone
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and (3) the institution submitting the data has no knowledge that the re-
maining information could be used to identify the research participant. 130
1. Voluntary and Informed Consent to Participate
By setting up the GWAS data sharing paradigm so that the collecting
institution codes the information before submitting it, institutions can take
the position that explicit informed consent is not necessary. The OHRP has
endorsed this position, determining that the GWAS repository does not
constitute human subjects research under 45 C.F.R. part 46 because the
information would be de-identified and used in research studies other than
that for which it was originally collected. 131 This means that, according to
the OHRP and its interpretation of 45 C.F.R. part 46, IRB review or certifi-
cation and informed consent considerations would not have been required
for the GWAS studies. 132
Yet the attempted de-identification of information raises problems.
Because genetic information is inextricably linked to the person from
whom it came, it is never possible to completely anonymize or de-identify
genetic data. 133 For example, I could fairly easily obtain a DNA sample
from someone by offering him or her a cup of coffee or by picking up a
piece of gum he or she threw out. The DNA contained in the person's sali-
va on the cup or in the gum could be sequenced for very little money and
then compared to research results. Or I could have my own genes analyzed
and compare them to sequences available on the Internet to determine in-
formation about any of my relatives who had participated in genetics re-
search, and my relatives (known or unknown) could do the same to me.
and fax numbers; email addresses; social security numbers; medical record numbers; health plan bene-
ficiary numbers; account numbers; certificate/license numbers; vehicle identifiers and serial numbers,
including license plate numbers; device identifiers and serial numbers; URLs; Internet Protocol (IP)
address numbers; biometric identifiers, including finger and voice prints; full face photographic images
and any comparable images; and any other unique identifying number, characteristic, or code. Id.
§ 164.514(b)(2)(i).
130. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,295 & n.6.
131. NAT'L INSTS. OF HEALTH, supra note 122, at I n.I. The NIH has stated that a data set of
genetic information and limited phenotype information is not "identifying" information because the
data set is only limited information and there is hardly any risk that someone can look at it and discern
the identity of the research participant, especially without a comparison sample. Nat'l lnsts. of Health,
Town Hall Meeting on a Proposed Policy for Sharing of Data Obtained in NIH Supported or Conducted
Genome-Wide Association Studies (GWAS), (NIH video broadcast Dec. 14, 2006). This may be a
distinction without a difference. Without a comparison list or database, my health plan number, medical
record number, or even Social Security number cannot be used to track me down. And other informa-
tion, such as my address, is not even uniquely mine. No one, however, has my exact genes.
132. NAT'L INSTS. OF HEALTH, supra note 122, at I n.l.
133. Zhen Lin et al., Genomic Research and Human Subject Privacy, 305 SCIENCE (SPECIAL
ISSUE) 183, 183 (2004).
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When the research subjects are members of a small group, or when data
includes pedigree information, it is possible to trace the data back to indi-
viduals. Even if a person's name is not included, information such as date,
birth location, or zip code, can be used to find a person's name. It might
one day be possible to predict the last name of the man a genetic sample
came from by looking at the Y chromosome. 134 And databases and records
are not immune to attacks from hackers. The broader the access to data and
information, the more likely a security breach can occur. 135 Information
contained in databases may reveal the presence or absence of disease, the
likelihood of developing a disease, environmental exposure, and medical
history that could be used to discriminate and could reveal harmful infor-
mation about family relationships (for example, paternity) or health status.
While the NIH has stated that "the GWAS database does not currently
involve human subjects research,"' 136 and although it recognizes that the
OHRP does not classify the research as human subjects research, the NIH
still requires some level of consent and IRB review. 137 According to the
NIH policy, submitted data should be accompanied by a certification from
the submitting institution, stating that it has reviewed and approved the
submission to the GWAS. 138 The final policy states that data submitted to
the repository must be accompanied by a certification from the responsible
IRB or other Institutional Officials certifying that the identities of the re-
134. DNA Fingerprinting Could Reveal Your Surname, REUTERS, Oct. 8, 2008.
135. Frequent incidences of theft, carelessness, computer hacking, and inadvertent disclosures
make it difficult to ensure that private information is truly secure. See Privacy Rights Clearinghouse, A
Chronology of Data Breaches, http://www.privacyrights.org/ar/ChronDataBreaches.htm#Total (last
visited Jan. 29, 2009) (reporting data breaches involving sensitive personal information since January
2005, with over 200 million records maintained by government and private entities accessed by unau-
thorized persons during that time period). Breaches have occurred not only at banks, universities, health
care entities, and private companies, but also at government agencies such as the U.S. Department of
Veteran's Affairs, the National Institutes of Health, the Internal Revenue Service, and the Department
of Transportation. See Larry Greenemeier, Security Breach: Feds Lose Laptop Containing Sensitive
Data-Again, Sci. AM., Mar. 25, 2008, http://www.sciam.com/article.cfm?id= security-breach-lost-
laptop (describing security breaches at General Electric, Fidelity Investments, the VA, the IRS, and the
DOT, as well as a March 2008 incident in which an NIH employee's laptop containing the names and
personal information of 2500 research participants was stolen).
136. NAT'L INSTS. OF HEALTH, supra note 122, at 11; see also Nat'l Insts. of Health, Town Hall
Meeting on a Proposed Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-
Wide Association Studies (GWAS), (NIH video broadcast Dec. 14, 2006). (indicating that GWAS data-
sharing does not constitute human research because the data that will be submitted is coded by the
submitting investigator and, therefore, is a "secondary use" of the data).
137. NAT'L INSTS. OF HEALTH, supra note 122, at I n.l.
138. Request for Information (RFI): Proposed Policy for Sharing of Data Obtained in NIH Sup-
ported or Conducted Genome-Wide Association Studies (GWAS), 71 Fed. Reg. 51,629, 51,630 (pro-
posed Aug. 30, 2006). Under the initial guidelines, an IRB would have provided a certificate to the
NIH, specifically noting that inclusion of the data in the GWAS repository is consistent with the re-
search participant's initial informed consent and identifying any uses of the data that are specifically
excluded in the informed consent. Id.
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search participants will not be disclosed. 139 Moreover, under the final poli-
cy, the certification must assure that an IRB reviewed and verified that
submission to the data repository is consistent with the informed consent of
the research participants; that the researcher's plan for de-identifying the
data is consistent with the standards outlined by the final policy; that it has
considered risks to individuals, their families, and groups or populations
associated with the submitted data; and that genotype and phenotype data
were collected in a manner consistent with the Common Rule. 140
In the final policy, the NIH acknowledges that there are informed
consent concerns regarding submitting data to the repository from both
studies undertaken after the policy was implemented ("prospective stu-
dies") and studies which collected samples and data or conducted research
before the policy was implemented ("retrospective studies"). 141 The NIH
expects that for prospective studies in which GWAS are conceived within
the design of the study at the time the research participants provide in-
formed consent, researchers will disclose to the participants that their geno-
type and phenotype information "will be" shared with other researchers
through the data repository. 142
For retrospective studies in which data that has been previously col-
lected is to be provided to the data repository, the NIH expects that the
institution submitting the information to the data repository will ensure that
the study materials are "appropriate for submission," 143 and gives individu-
al IRBs broad discretion in determining whether submitting data is "consis-
tent with" the terms in the original consent documents signed by the
participants. 144 It is up to the submitting institution and its IRB to deter-
mine if additional informed consent is required from research participants
before the information is submitted to the data repository. 145
In determining whether data submission to the NIH central repository
139. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. 49,290, 49,295 (proposed Aug. 28, 2007).
140. Id.; 45 C.F.R. § 46.111 (2007). The primary responsibility for protecting the privacy of indi-
vidual participants and for seeking consent from participants falls on the individual investigators who
collect the information. Nat'l Insts. of Health, Fact Sheet on Genome Wide Association Studies
(GWAS) Proposed Policy, Oct. 6, 2006, available at http://grants.nih.gov/grants/gwas/ fact-sheet.htm;
see Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association
Studies (GWAS), 72 Fed. Reg. at 49,292.
141. See Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide
Association Studies (GWAS), 72 Fed. Reg. at 49,293.
142. Id.; see also NAT'L INSTS. OF HEALTH, supra note 122, at 10.
143. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,293.
144. NAT'L INSTS. OF HEALTH, supra note 122, at 10-11.
145. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,293.
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is "consistent with" an original consent form, the IRB must consider the
scope of the consent form. 146 Submission may be considered appropriate if:
the consent form discusses the broad benefits of the research, rather than
benefits to the specific individual; it discusses the risks associated with
genetic research and risks consistent with data-sharing in GWAS; represen-
tations in the consent form are consistent with GWAS policies on returning
research results to individual patients; it discusses methods of privacy pro-
tection that are consistent with NIH GWAS policies; and it discusses
whether a subject may withdraw consent in language that is consistent with
NIH GWAS policies. 147 If data is acceptable for submission, the certifica-
tion to the NIH must list the types of research the data may be used for
according to the consent given by the participant.148 The NIH recognizes
that submitting pre-existing data or samples may require seeking additional
consent from research participants, and it may consider requests for fund-
ing to obtain this additional consent. 149
In this way, the NIH has provided admirable steps towards addressing
certain consent issues. Yet for retrospective studies, the policy might not
provide enough guidance to IRBs to determine if additional informed con-
sent is required. And, it is unlikely that any previous research contemplated
the broad data sharing now required by the NIH, so material information-
such as the risks associated with having a participant's data shared in this
manner-probably was not disclosed. Therefore, it is possible that no re-
trospective study obtained informed consent for the sharing of data and for
future studies using the information.
Additionally, it does not appear that institutions will necessarily give
potential participants the option of participating in research but not having
their data and information shared beyond the study confines. 150 The NIH
may decline to fund projects for which broad consent for data-sharing has
been refused by participants. 151 In this way, the policy might effectively be
both overinclusive and underinclusive, because participants might be pre-
vented from participating in research if they do not want their samples
shared. On the other hand, they might be involuntarily participating in re-
search for which they gave no specific consent.
146. NAT'L INSTS. OF HEALTH, supra note 122, at 10-11.
147. Id. at 12.
148. Id. at 10.
149. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. 49,290, 49,293 (proposed Aug. 28, 2007).
150. NAT'L INSTS. OF HEALTH, GENOME-WIDE ASSOCIATION STUDIES (GWAS): GUIDANCE FOR
DEVELOPING DATA-SHARING PLANS FOR GWAS 3-4 (2007), available at http://grants.nih.gov/
grants/gwas/gwas data sharingplan.pdf.
151. See id. at l.
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2. The Rights to Withdraw from Research and to Choose What Studies to
Participate or Not Participate In
Under the final policy, people might not have the option of withdraw-
ing their data and information from the studies. The policy allows submit-
ting investigators and their institutions to request removal of data on
individual participants from the data repository if research participants
decide to withdraw their consent. 152 Data that has already been distributed
to other investigators for approved research, however, will not be retrieved,
even if a research participant withdraws his or her consent. 153 In this way,
people cannot effectively withdraw from research. This is consistent with
the OHRP's opinion that the data sharing is not human subjects research.
Similarly, it appears that it would not be required that participants be
given the option of choosing which types of research they participate in,
although it has been suggested that a form of tiered consent be utilized.
Perhaps participants would choose to participate in a study searching for
genetic causes of obesity, but would not participate in a study of the genetic
causes of bipolar disease.
For retrospective studies, the submitting institution is given the re-
sponsibility of ensuring that consent is "consistent with" the scope of the
consent originally provided by the person. The IRB must consider whether
information sharing was precluded; whether certain types of research were
specifically excluded; whether research was limited to a certain location or
type of disease, and whether the consent specified how long data could be
stored, or who could conduct the research. 154 In making determinations, the
IRB must also consider whether commercial uses are precluded, whether
there are cultural concerns with sharing information, whether the informa-
tion was obtained from a child, or whether consent was obtained by
proxy. 155 If data is acceptable for submission, the certification to the NIH
must list the types of research the data may be used for according to the
consent given by the participant. 156 Each of these factors will certainly be
relevant to determining if the sharing is consistent with the original con-
sent. Nevertheless, "consistent with" is a vague term that could easily be
interpreted too loosely or too stringently, and it is not clear how much
weight each of these considerations should be given.
152. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg.at 49,293; NAT'L INSTS. OF HEALTH, supra note 122, at 8.
153. Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Associa-
tion Studies (GWAS), 72 Fed. Reg. at 49,293; NAT'L INSTS. OF HEALTH, supra note 122, at 8.
154. NAT'L INSTS. OF HEALTH, supra note 122, at 11-12.
155. Id. at 13.
156. Id. at 12.
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Some individuals will likely feel that these types of data sharing poli-
cies are acceptable, while other people may object. In a study of seeking to
determine peoples' preferences towards differing levels of consent by in-
terviewing individuals who recently participated in an epilepsy gene study,
eleven of fifteen respondents stated that it was "very or extremely impor-
tant that they be informed" when their information was shared with other
researchers. 157 Furthermore, thirteen of fifteen participants felt that it was
very or extremely important to have "general control over who could
access and use their DNA." 158
Yet people do not necessarily object to genetics research, and may in
fact view it very positively, especially depending on the nature of the study.
In a Swedish study, of those surveyed, 77.2% had a positive attitude toward
genetic research regarding the mapping of the genome, 85.3% had a posi-
tive attitude toward research designed to develop disease risk assessment
tools, 91.0% had a positive attitude toward research into diagnostic tools
and 92.5% had a positive attitude toward genetic research for the develop-
ment of new treatments. 159 The proportion of respondents who were unde-
cided ranged between 6.6% and 18.9% depending on the purpose of the
research, and those who held negative views ranged from 0.9% (regarding
new treatments) and 3.9% (regarding genome mapping). 160
Another study found a difference between U.S. individuals' general
support for a large scale genetic study and their willingness to actually
participate in the study. 161 Eighty-four percent of those surveyed felt that
the study either definitely (25%) or probably (59%) should be done but
willingness to actually participate varied from 51% to 73% depending on
the details of the proposed study. 162 A survey that aggregated the data from
thirty studies conducted in the U.S and abroad came to conclusion that
"people want to control whether their samples are used for research and
that most are willing to contribute samples."' 163 With such widely diverse
views and statistics, the main certainty is that these studies present issues
157. Amy L. McGuire et al., DNA Data Sharing: Research Participants' Perspective, 10 GENET.
MED. 46, 50 (2008).
158. Id.
159. Asa Kettis-Lindblad et al., Genetic Research and Donation of Tissue Samples to Biobanks,
What do potential sample donors in the Swedish General Public Think?, 16 EUR. J. PUBLIC HEALTH,
433, 435 (2005).
160. Id.
161. David Kaufmnan et al., Subjects Matter: A Survey of Public Opinions About a Large Genetic
Cohort Study, 10 GENET. MED. 831, 833 (2008).
162. Id.
163. David Wendler, One-time General Consent for Research on Biological Samples, 332 BRIT.
MED. J. 544, 546 (2006).
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that are difficult to address.
3. Epilogue
Eight months after its data sharing policy went into effect the NIH
removed genetic information from internet databases available to the pub-
lic. 164 Recently released research had demonstrated that new DNA analysis
methods could be used to determine whether an individual's genetic sample
were present in a sample that might contain DNA from as many as one
thousand people. 165 Previously, it had been widely accepted that it would
not be possible to identify a person when a sample contained DNA from
many people or when data that resulted from analyzing the genetic makeup
of many people were pooled or presented in a summary-level fashion. 166
The new research laid that theory to rest, and fortunately the NIH reacted
quickly by pulling aggregate genetic data from its publicly available data-
bases. 167
B. NCI Best Practices for Biospecimen Resources
With an annual budget of several billion dollars, the National Cancer
Institute is the agency responsible for the federal government's cancer re-
search initiatives. In 2004, a report for the National Cancer Advisory Board
showed substantial differences in the way biorepositories are managed
across the NCI. 168 The study revealed that "NCI-supported biorepositories
are not optimized in terms of operational, legal, and ethical policies and
procedures, nor are they coordinated to provide a unique resource val-
ue." 169 In response to these findings, the NCI established a committee to
164. NAT'L INSTS. OF HEALTH, MODIFICATIONS TO GENOME-WIDE ASSOCIATION STUDIES
(GWAS) DATA ACCESS, 1 (2008), available at http://grants.nih.gov/grants/gwas/data-sharing-policy-
modifications_20080828.pdf. The Los Angeles Times characterized this as an "unusual step" to "quietly
block[] public access." Jason Felch, DNA Profiles Blocked from Public Access, L.A. TIMES, Aug. 29,
2008, at 31. Other research has revealed it may be possible to use DNA analysis of the Y chromosome
to determine the last name of the unknown male individual who provided the genetic material. Ben
Hirschler, DNA Fingerprinting Could Reveal Your Surname, MSNBC.COM , Oct. 8, 2008,
http://www.msnbc.msn.com /id/27084334/.
165. See Nils Homer et al., Resolving Individuals Contributing Trace Amounts of DNA to Highly
Complex Mixtures Using High-Density SNP Genotyping Microarrays, 4 PLOS GENETICS, Aug. 2008, at
1-2, 7, 9, http://www.plosgenetics.org/article/info%3Adoi%2FI 0.1371%2 Fjoumal.pgen. 1000167.
166. Id. at 9.
167. NAT'L INSTS. OF HEALTH, supra note 164, at 1. Before the information was taken down from
the NIH's website, it was downloaded at least 140 times. Jason Felch, DNA Profiles Blocked from
Public Access, L.A. TIMES, Aug. 29, 2008, at 31.
168. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. 25,184, 25,184
(proposed Apr. 28, 2006).
169. Id.
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advise it and to make specific recommendations on policy and operational
issues with respect to NCI-supported biorepositories and tissue and data
sharing. 17 0
As a result of the committee's work, the NCI has released its Best
Practices for Biospecimen Resources (the "Best Practices"), which is to be
followed by NCI-supported biorepositories on a voluntary basis. 171 The
Best Practices were released in June 2007, after approval by the National
Cancer Advisory Board. Prior to writing the Best Practices, the NCI issued
First-Generation Guidelines for NCI-Supported Biorepositories (the
"Guidelines"), for which it requested public comment. 172 The NCI received
sixty-one responses from academic institutions, professional societies, pri-
vate industries, foundations, advocacy groups, and governmental agen-
cies. 173 According to the NCI, cancer centers and biorepositories provided
the majority of the comments, but because the comments are not publicly
available, it is not known how many patient rights groups commented, how
many organizations that commented had commercial interests in the way
biorepositories are run, or what the content of the comments was. 174
As with the NIH's plan for data sharing in GWAS studies, in some
ways the NCI's plan might not fully protect the interests of people who
participate in research, and yet it has made changes to its proposal that are
beneficial to research participants.
1. Voluntary and Informed Consent to Participate
As with its predecessor document (the Guidelines), NCI's Best Prac-
tices addresses1 75 the need for voluntary and informed consent for partici-
pation in research. Yet, unlike in the Guidelines, the Best Practices states
that informed consent might not be necessary, even for human subjects
research, if the research is exempt under 45 C.F.R. § 46.101(b), or if an
institutional review board grants the research a waiver under § 46.116(c)-
(d). 176 Thus, after the commentary period, it appears as though the NCI
might be adopting a view that certain research is exempt from the regula-
tions governing human subjects research, or that informed consent can be
170. NAT'L CANCER INST., BEST PRACTICES FOR BIOSPECIMEN RESOURCES 1 (2007),
http://biospecimens.cancer.gov/global/pdfs/NCIBestPractices_060507.pdf.
171. Id. § A.2.
172. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. at 25,184.
173. NAT'L CANCER INST., BEST PRACTICES FOR BIOSPECIMEN RESOURCES 2 (2007) (unpublished
draft, on file with author).
174. Id.
175. NAT'L CANCER INST., supra note 170, § C.2.
176. Id.
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waived. However, neither of the regulatory provisions cited by the NCI are
applicable to tissue that is collected for research protocols. 45 C.F.R.
§ 46.101 (b)(4) creates an exemption to the informed consent regulations for
research that is conducted on existing pathological or diagnostic specimens
if the specimens are not linked to the patients' identities. 177 Samples col-
lected for research purposes are not already "existing," at least with respect
to the study for which they were collected. They also were not collected for
the detection of disease, so they do not satisfy the latter part of the excep-
tion. 45 C.F.R. § 46.116(c) is inapplicable because it covers research re-
garding public benefits (such as welfare), 178 and § 46.116(d) only applies
when the risk to the participant is minimal, 179 which is not the case in ge-
netics research. 180
Although when it had originally drafted the standards, the NCI had
contemplated providing biorepositories with a sample consent template,
which could have been adapted to conform to relevant state laws and poli-
cies and for approval by the appropriate IRB, 181 the Best Practices does not
contain a sample consent form. The NCI suggests that, as part of informed
consent, research participants should be able to select general types of re-
search for which their biospecimens may be used, including future stu-
dies. 182 Both in the model informed consent attached to the Guidelines 183
and under the Best Practices (which does not have a sample informed con-
sent document, but which does give examples of consent options), 184 par-
ticipants would be given tiered options for their participation; for example,
the consent form could first ask whether the participants' tissue could be
used in unspecified cancer research, and second, whether their tissue could
be used in studies of other diseases, such as "diabetes, Alzheimer's disease
or heart disease."
But both the Guidelines and the Best Practices seem to ignore a third
category of research-research that is potentially objectionable to some
people, such as research into mental illness, addictive tendencies, or crimi-
nal behavior. A participant may not want to provide tissue for research that
177. 45 C.F.R. § 46.101(b)(4) (2007).
178. Id. §46.116(c).
179. Id. § 46.116(d).
180. See, e.g., OFFICE FOR HUMAN RESEARCH PROTS., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
INSTITUTIONAL REVIEW BOARD GUIDEBOOK ch. 5, § H (1993), available at http://www.hhs.gov/
ohrp/irb/irbchapter5ii.htm#h 12.
181. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. 25,184, 25,187
(proposed Apr. 28, 2006).
182. Id. at 25,184; NAT'L CANCER INST., supra note 170, § C.2.2.7.
183. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. at 25,197.
184. NAT'L CANCER INST., supra note 170, § C.2.2.7.
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offends his or her religious or moral beliefs, as has happened with indigen-
ous people, religious sects, and certain minority groups. Such was the situa-
tion for the Havasupai. The tribal members consented to providing their
tissue for use in diabetes studies, but objected to the unfettered use of their
tissue in research on mental illness and research that contradicted their
beliefs about their origins. 185 Similarly, many people object to the patent-
ing of human genes. 186 They would choose not to participate in research
that leads to gene patents.
Participants may find the tiered consent for future or non-specified
research suggested by the NCI to be inadequate to ensure informed consent
to research because it is broadly worded; asks people to give away their
rights; and asks people to consent to future research, the risks of which are
unknown. Both the prior NCI Guidelines and its subsequent Best Practices
note that obtaining informed consent from human research subjects for the
collection and storage of biospecimens and for their use in future studies is
difficult because the specifics of future research may be unknown when the
specimen is collected. 187 Not only is the exact nature of future research
difficult to contemplate because it is not known what technology will exist
in the future, but the exact risks of participating in this research are un-
known and impossible to predict. This is one reason participants must be
allowed to effectively withdraw from research in which they no longer
wish to participate.
2. Withdrawal of Consent and Discontinuation of Participation
Both the NCI Guidelines and the subsequent NCI Best Practices rec-
ognize participants' right to withdraw from research.188 The Guidelines
discuss the participants' retention of the power to withdraw their consent
during the "analysis phase of identifiable private information."' 189 Under
the NCI's earlier Guidelines, if a research participant did, in fact, withdraw
his or her consent, then the individual biospecimen contained in the biore-
pository would be withdrawn from the biorepository and attempts would
185. Dalton, supra note 104, at 500-01.
186. See Lori Andrews et al., When Patents Threaten Science, 314 SCIENCE 1395, 1395-96 (2006);
see also John Conley, Gene Patents and the Product of Nature Doctrine, 84 CHI.-KENT L. REv. 109
(2009); Debra Harry, Indigenous Peoples and Gene Disputes, 84 CHI.-KENT L. REv. 147 (2009); Seth
Shulman, Upstream Without A Paddle: Gene Patenting and the Protection of the 'Infostructure,' 84
CHI.-KENT L. REv. 91 (2009).
187. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. at 25,194; see
also NAT'L CANCER INST., supra note 170, § C.2.2.7.
188. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. at 25,194;
NAT'L CANCER INST., supra note 170, § C.2.2.9.
189. First-Generation Guidelines for NCI-Supported Biorepositories, 71 Fed. Reg. at 25,194.
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be made to retrieve any sample of that specimen that has already been dis-
tributed. The NCI recommended that once consent was withdrawn, the
biospecimen samples should be destroyed or stripped of all direct and indi-
rect identifying information. 190 It stated that this latter option should be
included in the initial informed consent form. 191
As with the NCI Guidelines, the subsequent NCI Best Practices states
that the "[i]nformed consent documents should highlight the human sub-
ject's ability to discontinue participation and describe what will take place
should this occur." 192 But the Best Practices appears to handle the recall of
already disseminated samples differently. Under the Best Practices, if a
participant discontinues participation, samples that have been transferred
need not be recalled. 193 However, the biorepository is "ethically obligated"
to notify recipients of the tissue that the participant withdrew consent. 194
Then, the recipient investigator would be required to withdraw the partici-
pant's tissue from research if the biospecimen were individually identifia-
ble.' 95 The collecting institution and the recipient investigator are given
three options: (1) stop using the individually identifiable specimens and
private information (which includes medical record information); (2) re-
move the individually identifiable information and eliminate private infor-
mation; or (3) destroy the sample and information. 196 The NCI Best
Practices contains a provision similar to the Guidelines reminding investi-
gators to be aware of cultural issues and to return the sample to the person
it came from or properly destroy it as appropriate. 197
The final Best Practices thus has standards in place that would allow
research to continue on a participant's tissue even after a participant speci-
fies that she is discontinuing participation. First, the NCI does not require
that samples be recalled from recipient investigators, even if the collecting
institution knows which coded sample belongs to the participant. It makes
sense that a participant's sample cannot be withdrawn from research if his
or her name has been irretrievably unlinked from the sample and there is no
way to locate it; coded samples, however, are a different story. Regardless
of whether the recipient investigator has the code, the information in the
190. Id. at 25,194.
191. Id.









code can be readily ascertained by the collecting institution. Next, the
NCI's Best Practices allows the receiving researcher to remove the partici-
pant's identity and continue to use the sample. Tissue contains uniquely
identifiable DNA, so it is never possible to completely de-identify it.198
And, allowing tissue to be used after a person withdraws consent means
that tissue from the person is being used in research without his or her con-
sent. The participant might not realize he or she can never effectively with-
draw from research.
The NCI Best Practices illustrates how even governmental agencies
have interpreted the regulations designed to protect the rights of individuals
in a manner that may not comport with what the individuals might prefer,
while at the same time providing important protections that courts and oth-
er institutions have overlooked.
CONCLUSION
Evidence demonstrates that people do have strong preferences about
what is done with their tissue after it is removed from their body. They care
about who conducts the research, what type of research is undertaken,
whether their samples are going to be shared with other institutions or bio-
tech companies, and the length of time their sample will be stored. People
also tend to be interested in knowing what the financial incentives for con-
ducting the research are, whether their physician or the person collecting
the tissue has a personal financial stake in their participation, and whether
the study is funded by a company or pharmaceutical company. 199 But dis-
closing this information need not make researchers fret that participation
will decrease; disclosing this information may actually make people more
likely to agree to participate because they feel they can make a reasoned
decision about whether the particular potential conflict of interest worries
198. See Amy L. McGuire & Richard A. Gibbs, No Longer De-Identified, 312 SCIENCE 370, 370
(2006) (citing Zhen Lin et al., supra note 133, at 183).
199. In a study of Swedish participants, a significant minority (18.7%), said that their decision to
participate in research would be affected by whether funding was provided by a private company versus
a public or independent source. Kettis-Lindblad et al., supra note 159, at 435. But this information does
not necessarily prevent people from participating. In a survey of Americans with chronic illnesses,
results revealed that most potential research participants wanted to be informed about potential conflict
of interest even though they still would want to participate. S.Y.H. Kim et al., Potential Research
Participants' Views Regarding Researcher and Institutional Financial Conflicts of Interest, 30 J. MED.
ETHICs 73, 76 (2004). For example, 81% of potential research participants with heart disease would
want to know if the study received funding from the company that manufactures the drug being studied
but only 2% of respondents indicated that they would not participate in the study. Id. at 76. In fact, 46%
of respondents indicated that they would be more likely to participate in the trial, citing reasons such as,
"I would feel better about it if it was a well known company funding the project." Id. at 76, 78.
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them.200 Yet there is a value to asking people even if the answer is "yes."
Allowing individuals to make decisions about research will help main-
tain trust in researchers and research institutions. Trust is an important fac-
tor affecting a person's willingness to participate in research. Some patients
are more willing to consent to tissue banking and unspecified future re-
search if the institution enrolling the patient is a community hospital or
private practice rather than a large academic research institution.201 Other
people may decide to participate in research based on the recommendation
of a trusted physician. 202 A recent study found that respondents who indi-
cated that they trusted medical researchers were significantly more likely to
agree that they felt "very positive" about genetic research. 203 But levels of
trust can vary depending on the reputation of the institution or individual
researchers. 204 Potential participants who are less trusting of medical re-
searchers are more likely to want their permission sought for future re-
search on their tissue samples.205
Genetics-based research holds many promises for the future-the de-
tection of genetic propensities to certain diseases, and the better prevention
and treatment of diseases. Research depends on people willing to partici-
pate in research studies. There is a recent trend to find ways to argue that
ethical and legal protections that were created to protect people who partic-
ipate in research should be interpreted in a way that might ultimately un-
dermine the research enterprise. If this trend continues, and if institutions
and governmental agencies decide to ignore evidence about how people
feel about the use of their tissue in research, research may suffer as people
become increasingly unwilling to participate or demand that their tissue not
be used in future studies. True transparency in the research system and
adherence to the legal and ethical principles that underlie the research sys-
tem should be encouraged as a means for greater participation in research.
200. Kim, et al., supra note 199, at 78.
201. Thomas Malone et al., High Rate of Consent to Bank Biologic Samples for Future Research:
The Eastern Cooperative Oncology Group Experience, 94 J. NAT'L CANCER INST. 769, 770 (2002).
202. M. Wilcox & S. Schroer, The Perspective of Patients with Vascular Disease on Participation
in Clinical Trials, 12 J. VASC. NURSING 112, 113 (1994).
203. Gail Henderson et al., Great Expectations: Views of Genetic Research Participants Regarding
Current and Future Genetic Studies, 10 GENET. MED. 193, 196 (2008).
204. Malone et al., supra note 201, at 770.
205. S.C. Hull et al., Patients' Views On Identifiability of Samples and Informed Consent for Genet-
ic Research, 8 AM. J. BIOETHICS 62, 66 (2008).
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